Anticipate significant positive stock movement ahead of the ASCO plenary presentation on May 31, 2026, especially if full data confirms survival benefit and safety profile. This could accelerate FDA approval and position daraxonrasib as a new standard of care in a high-mortality indication with limited options.
RVMD drugs
RVMD drug pipeline →How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Apr 21 $148.90entry
- T+1 · 7mo ago −4.97%α −5.99% · $141.50
- T+5 · 7mo ago −2.73%α −3.82% · $144.83
- T+20 · 6mo ago −3.04%α −7.96% · $144.37
- T+60 · 4mo ago +20.34%α +13.44% · $179.18
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Revolution Medicines announced that detailed results from its Phase 3 RASolute 302 trial of daraxonrasib in metastatic pancreatic cancer will be presented at ASCO 2026, following previously reported unprecedented overall survival benefit. The drug met all primary and key secondary endpoints, including statistically significant improvements in progression-free and overall survival versus chemotherapy.
Key Facts
- Daraxonrasib demonstrated statistically significant and clinically meaningful improvement in both PFS and OS vs standard chemotherapy in previously treated metastatic PDAC.
- Results from the Phase 3 RASolute 302 trial will be presented in a Plenary Session at ASCO 2026, a high-profile venue indicating clinical importance.
- FDA has granted Breakthrough Therapy and Orphan Drug Designations for daraxonrasib; it is also part of the FDA Commissioner’s National Priority Voucher program.
- The trial included patients with various RAS mutations (G12D, G12V, G12R) and RAS wild-type, broadening potential applicability.
- Daraxonrasib is an oral, once-daily RAS(ON) multi-selective inhibitor, offering a convenient alternative to intravenous chemotherapy.
Financial Impact
Potential blockbuster drug with peak sales estimates exceeding $5B annually in metastatic pancreatic cancer alone, based on unmet need and trial results.
Risk Factors
- Regulatory approval is not guaranteed despite Breakthrough designation; FDA may require additional data.
- Safety concerns could emerge in full dataset, limiting commercial potential.
- Competition from other RAS inhibitors in development may affect market share post-approval.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3278211 |
Track record
44 reports on RVMD
6 of 9 bullish or bearish reports moved the stock their way by T+60. Best: +31.56% at T+60 after the Apr 21, 2026 report. 16 of 17 went positive at some point.
Filters
- Nov 16, 2026today 144 Neutral 3/10 Entry $167.00 Now $166.87 −0.08% settles Feb 16
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $168.20 Now $166.87 −0.79% settles Feb 12
- Nov 13, 20263d ago Insider Cluster Neutral 2/10 Entry $176.02 Now $166.87 −5.20% settles Feb 12
- Nov 12, 20264d ago 144 Neutral 3/10 Entry $176.35 Now $166.87 −5.38% settles Feb 10
- Nov 5, 202611d ago SC 13G/A Neutral 3/10 Entry $177.65 Now $166.87 −6.07% settles Feb 3
- Nov 4, 202612d ago 8-K Bullish 7/10 No price data
- Nov 4, 202612d ago Press Release Neutral 5/10 Entry $177.65 Now $166.87 −6.07% settles Feb 3
- Oct 30, 202617d ago SC 13G Neutral 3/10 Entry $191.31 Now $166.87 −12.78% settles Jan 28
- Oct 23, 202624d ago Institutional Cluster Bullish 4/10 Entry $186.99 Now $166.87 −10.76% settles Jan 21
- Oct 21, 202626d ago Press Release Neutral 1/10 Entry $187.69 Now $166.87 −11.09% settles Jan 20
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers